

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7183516

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
CAPITAL ONE, NATIONAL ASSOCIATION	01/04/2022

RECEIVING PARTY DATA

Name:	COVIS PHARMA B.V.
Street Address:	GRAFENAUWEG 12
City:	ZUG
State/Country:	SWITZERLAND
Postal Code:	6300

PROPERTY NUMBERS Total: 27

Property Type	Number
Patent Number:	6767901
Patent Number:	8383611
Patent Number:	8481516
Patent Number:	8268240
Patent Number:	8182824
Patent Number:	8258124
Patent Number:	7879833
Patent Number:	6350768
Patent Number:	8464707
Patent Number:	8435497
Patent Number:	D582544
Patent Number:	9422327
Patent Number:	7468433
Patent Number:	6642262
Patent Number:	8440210
Patent Number:	8163299
Patent Number:	8029811
Patent Number:	7736673
Patent Number:	8288445
Patent Number:	7947744

PATENT

Property Type	Number
Patent Number:	8371292
Patent Number:	8486923
Patent Number:	7879832
Application Number:	14865637
Application Number:	13688659
Application Number:	14238055
Application Number:	16440557

CORRESPONDENCE DATA

Fax Number: (212)492-0900

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2123733900

Email: schopra@paulweiss.com, mangelopoulos@paulweiss.com, mccguire@paulweiss.com

Correspondent Name: SHRUTI CHOPRA

Address Line 1: 1285 AVENUE OF THE AMERICAS

Address Line 2: PAUL WEISS RIFKIND WHARTON & GARRISON LLP

Address Line 4: NEW YORK, NEW YORK 10019

ATTORNEY DOCKET NUMBER: 022989-0000

NAME OF SUBMITTER: SHRUTI CHOPRA

SIGNATURE: /Shruti Chopra/

DATE SIGNED: 02/18/2022

Total Attachments: 4

source=Covis - Patent Release (December 2021) [Executed Version](15572365.1)#page1.tif

source=Covis - Patent Release (December 2021) [Executed Version](15572365.1)#page2.tif

source=Covis - Patent Release (December 2021) [Executed Version](15572365.1)#page3.tif

source=Covis - Patent Release (December 2021) [Executed Version](15572365.1)#page4.tif

RELEASE OF SECURITY INTEREST IN PATENTS

January 4, 2022

WHEREAS, pursuant to that certain Short-Form Patents Security Agreement, dated as of March 10, 2020 (the "Patent Security Agreement"), recorded in the United States Patent and Trademark Office ("USPTO") on March 12, 2020 under Reel/Frame 052095/0262, by COVIS PHARMA B.V. ("Releasee") to CAPITAL ONE, NATIONAL ASSOCIATION, as collateral agent ("Releasor"), Releasee granted to Releasor, for the benefit of the Secured Parties (as defined in the Patent Security Agreement), a security interest in all of its right, title and interest in, to and under all the patents and patent applications, whether owned or at any time acquired, of Releasee issued by, or for which applications have been filed with the USPTO, including, without limitation, the patents and applications listed on the annexed Schedule A, and all related patents and applications thereto, including all reissuances, continuations, continuations-in-part, revisions, extensions, re-examinations thereof, any patents and patent applications claiming priority to said patents and patent applications or from which said patents and patent applications claim priority, and pending applications associated therewith and all proceeds thereof, including, without limitation, any and all causes of action which may exist by reason of infringement thereof and any and all damages arising from past, present and future violations thereof (collectively, the "Patent Collateral"); and

WHEREAS, Releasee has requested, and Releasor has agreed to execute, acknowledge and deliver, this Release of Security Interest in Patents to terminate the Patent Security Agreement and confirm the release, relinquishment and discharge of its continuing security interest in, to and under the Patent Collateral.

NOW, THEREFORE, in consideration of and in exchange for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, Releasor hereby agrees as follows:

Release of Security Interest. Releasor hereby, without any representation or warranty and without any recourse to Releasor, terminates the Patent Security Agreement and hereby terminates, releases, relinquishes and discharges its continuing security interest in, to and under the Patent Collateral and transfers and assigns to Releasee any right, title or interest Releasor may have in, to and under the Patent Collateral.

Releasor further agrees to execute and deliver to Releasee any and all further documents and instruments, and do any and all further acts which Releasee (or its agents or designees) reasonably request, at Releasee's sole cost and expense, in order to confirm this Release of Security Interest in Patents and Releasee's right, title, and interest in or to the Patent Collateral.


Releasor hereby authorizes Releasee or Releasee's authorized representative to (i) record this Release of Security Interest in Patents with the USPTO and/or (ii) otherwise record or file this Release of Security Interest in Patents in the applicable governmental office or agency.

THIS RELEASE OF SECURITY INTEREST IN PATENTS SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK.

[Remainder of page intentionally left blank.]

IN WITNESS WHEREOF, Releasor has caused this Release of Security Interest in Patents to be duly executed as of the date first written above.

CAPITAL ONE, NATIONAL ASSOCIATION

By: 
Name: Alaina Powers
Title: Duty Authorized Signatory

SCHEDULE A**PATENTS**

Patent	Jurisdiction	Application Number/ Filing Date	Patent Number/ Issue Date	Status	Owner
Aqueous suspensions of ciclesonide for nebulisation	United States	14865637 25-SEP-2015	Not Available	Pending	COVIS PHARMA B.V.
Ciclesonide contained pharmaceutical composition for application to mucosa	United States	10110629 15-JUL-2002	6767901 27-JUL-2004	Registered	COVIS PHARMA B.V.
Ciclesonide containing aqueous pharmaceutical composition	United States	10110632 15-JUL-2002	8383611 26-FEB-2013	Registered	COVIS PHARMA B.V.
Ciclesonide containing aqueous pharmaceutical composition	United States	13688659 29-NOV-2012	Not Available	Pending	COVIS PHARMA B.V.
Ciclesonide containing sterile aqueous suspension	United States	12448351 21-AUG-2009	8481516 09-JUL-2013	Registered	COVIS PHARMA B.V.
Ciclesonide-containing sterile aqueous suspension	United States	12461647 19-AUG-2009	8268240 18-SEP-2012	Registered	COVIS PHARMA B.V.
Ciclesonide-containing sterile aqueous suspension	United States	10519484 21-JUL-2005	8182824 22-MAY-2012	Registered	COVIS PHARMA B.V.
Combination medicament	United States	12973350 20-DEC-2010	8258124 04-SEP-2012	Registered	COVIS PHARMA B.V.
Combination medicament	United States	10537356 03-JUN-2005	7879833 01-FEB-2011	Registered	COVIS PHARMA B.V.
Combination of riluzole and of gabapentin and its use as a medicament	United States	09718543 22-NOV-2000	6350768 26-FEB-2002	Registered	COVIS PHARMA B.V.
Compliance monitor and method	United States	10572316 17-MAR-2006	8464707 18-JUN-2013	Registered	COVIS PHARMA B.V.
Formoterol of and ciclesonide combination	United States	10559383 06-DEC-2005	8435497 07-MAY-2013	Registered	COVIS PHARMA B.V.
Metered dose inhaler	United States	29283277 09-AUG-2007	D582544 09-DEC-2008	Registered	COVIS PHARMA B.V.
Pharmaceutical aerosol product for administration by oral or nasal inhalation	United States	14238055 10-FEB-2014	Not Available	Pending	COVIS PHARMA B.V.
Process for preparing crystalline ciclesonide with defined particle size	United States	10549631 07-NOV-2005	9422327 23-AUG-2016	Registered	COVIS PHARMA B.V.

Process for the production of 16,17-[(cyclohexylmethylene)bis(oxy)]11,21-dihydroxy-pregna-1,4dien-3,20-dion or its 21isobutyrate by transketalisation	United States	10399689 04-AUG-2003	7468433 23-DEC-2008	Registered	COVIS PHARMA B.V.
Riluzole and alpha-tocopherol combination	United States	09854318 11-MAY-2001	6642262 04-NOV-2003	Registered	COVIS PHARMA B.V.
Stabilized pharmaceutical product	United States	13437569 02-APR-2012	8440210 14-MAY-2013	Registered	COVIS PHARMA B.V.
Stabilized pharmaceutical product	United States	13219046 26-AUG-2011	8163299 24-APR-2012	Registered	COVIS PHARMA B.V.

Patent	Jurisdiction	Application Number/ Filing Date	Patent Number/ Issue Date	Status	Owner
Stabilized pharmaceutical product	United States	12771557 30-APR-2010	8029811 04-OCT-2011	Registered	COVIS PHARMA B.V.
Stabilized pharmaceutical product	United States	11259495 26-OCT-2005	7736673 15-JUN-2010	Registered	COVIS PHARMA B.V.
Stable pharmaceutical products	United States	12951608 22-NOV-2010	8288445 16-OCT-2012	Registered	COVIS PHARMA B.V.
Stable pharmaceutical products	United States	11325875 05-JAN-2006	7947744 24-MAY-2011	Registered	COVIS PHARMA B.V.
Use of ciclesonide for the treatment of respiratory diseases	United States	10571311 09-MAR-2006	8371292 12-FEB-2013	Registered	COVIS PHARMA B.V.
Use of ciclesonide for the treatment of respiratory diseases	United States	16440557 13-JUN-2019	Not Available	Pending	COVIS PHARMA B.V.
Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis	United States	12973414 20-DEC-2010	8486923 16-JUL-2013	Registered	COVIS PHARMA B.V.
Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis	United States	10524821 18-FEB-2005	7879832 01-FEB-2011	Registered	COVIS PHARMA B.V.